Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy
暂无分享,去创建一个
Y. Lotan | S. Shariat | P. Karakiewicz | S. Egawa | I. Resch | D. D’andrea | M. Moschini | H. Fajkovic | M. Abufaraj | B. Pradère | V. Schuettfort | J. Teoh | D. Scherr | E. Compérat | H. Mostafaei | R. Sari Motlagh | K. Mori | S. Katayama | P. Rajwa | N. Grossmann | E. Laukhtina | F. Quhal
[1] K. Owzar,et al. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib , 2020, Molecular Cancer Therapeutics.
[2] A. Briganti,et al. A Systematic Review and Meta-analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. , 2020, The Journal of urology.
[3] S. Shariat,et al. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis , 2020, International Journal of Clinical Oncology.
[4] J. Witjes,et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.
[5] S. Shariat,et al. Differential Effect of Sex on Outcomes After Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. , 2020, The Journal of urology.
[6] P. Grivas,et al. The utility of next generation sequencing in advanced urothelial carcinoma. , 2019, European urology focus.
[7] Shahrokh F. Shariat,et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.
[8] J. Witjes,et al. Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer , 2019, BJU international.
[9] M. R. Kim,et al. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer , 2018, International journal of molecular sciences.
[10] S. Shariat,et al. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer , 2018, Expert review of molecular diagnostics.
[11] F. Mahjoubi,et al. Study of Vcam-1 Gene Expression in Normal and Tumoral Tissues in Patients With Colorectal Cancer , 2017 .
[12] G. Petroni,et al. Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC) , 2017, Cancer.
[13] M. R. Kim,et al. A Human Antibody That Binds to the Sixth Ig-Like Domain of VCAM-1 Blocks Lung Cancer Cell Migration In Vitro , 2017, International journal of molecular sciences.
[14] A. Vickers,et al. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. , 2015, European urology.
[15] G. Bendas,et al. Vascular cell adhesion molecule‐1 (VCAM‐1)—An increasing insight into its role in tumorigenicity and metastasis , 2015, International journal of cancer.
[16] Yair Lotan,et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. , 2015, European urology.
[17] M. Hollstein,et al. VEGF-A isoforms differentially regulate ATF-2–dependent VCAM-1 gene expression and endothelial–leukocyte interactions , 2014, Molecular biology of the cell.
[18] F. Tas,et al. Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy , 2014, Tumor Biology.
[19] F. Montorsi,et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.
[20] C. Dinney,et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort , 2011, BJU international.
[21] Y. Lotan,et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. , 2010, Urologic oncology.
[22] Yair Lotan,et al. Statistical consideration for clinical biomarker research in bladder cancer. , 2010, Urologic oncology.
[23] Yair Lotan,et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.
[24] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[25] T. Wheeler,et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Y. Iwamoto,et al. The Activity of Soluble VCAM-1 in Angiogenesis Stimulated by IL-4 and IL-13 , 2000, The Journal of Immunology.
[27] A. Blann,et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. , 2000, Journal of the National Cancer Institute.
[28] Yair Lotan,et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.
[29] R. Hwang,et al. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. , 2005, The Journal of clinical investigation.